Tycho B.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase I Study to Evaluate the Safety of STAb-T19 Genetically Modified T Cells Secreting αCD19xαCD3 Bispecific Antibodies in Patients with Malignant B-cell Neoplasms
- Phase 3 Study of Lisaftoclax (APG-2575) and Acalabrutinib in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients
- Phase 1b Evaluation of JNJ-80948543 with CD3 T-Cell Engagers in Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies
Data & Insights
Has run more than one trial at 4 of 77 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating various forms of B-cell non-Hodgkin lymphoid malignancies, with particular expertise in managing both newly diagnosed and relapsed/refractory cases.
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Mantle Cell Lymphoma
Their clinical focus includes innovative therapeutic approaches for these conditions.
Lymphoma Subtypes
The investigator has developed expertise in treating various lymphoma subtypes, including marginal zone lymphoma and follicular lymphoma.
- Richter's Transformation
- Waldenström's Macroglobulinemia
- B-cell Lymphoid Malignancies
Their work encompasses multiple therapeutic strategies for these distinct lymphoma variants.
Novel Therapeutics
The investigator works with targeted therapeutic approaches for hematologic malignancies, including evaluation of new treatment combinations.
- CD3 T-Cell Engagers
- BTK Inhibitors
- Combination Therapies
Their research includes assessment of novel agents for various lymphoid malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.